Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.63 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.59 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.59 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016346 | 0.93 | SRD5A2 (0.56) | SRD5A2LTB4RLTB4R2MEN1NPC1 | |
| SCHEMBL3102127 | 0.87 | SRD5A2 (0.67) | SRD5A2LTB4RLTB4R2PLA2G4AMCL1 | |
| SCHEMBL13802531 | 0.85 | SRD5A2 (0.74) | SRD5A2LTB4RLTB4R2PLA2G4AMEN1 | |
| SCHEMBL8693185 | 0.83 | MCL1 (0.58) | MCL1MEN1KMT2A | |
| SCHEMBL700511 | 0.83 | SRD5A2 (0.73) | SRD5A2LTB4RLTB4R2PLA2G4AMEN1 | |
| SCHEMBL2969223 | 0.82 | SRD5A2 (0.57) | SRD5A2LTB4RLTB4R2MEN1NPC1 | |
| SCHEMBL7686434 | 0.82 | PLA2G4A (0.46) | PLA2G4AMCL1 | |
| SCHEMBL13802519 | 0.82 | SRD5A2 (0.72) | SRD5A2LTB4RLTB4R2PLA2G4AMCL1 | |
| SCHEMBL7686577 | 0.81 | NOD2 (0.49) | MEN1KMT2A | |
| SCHEMBL3639124 | 0.80 | SRD5A2 (0.69) | SRD5A2LTB4RLTB4R2PLA2G4AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342205-B1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARM INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20150336966-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2015-11-26 | — | — | US | disclosed |
| US-9108969-B2 | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders | ARENA PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20130184307-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8415484-B2 | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders | ARENA PHARMACEUTICALS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2342205-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20110160243-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals ,Inc. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2010027431-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336966-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR5, S1PR3 | SRD5A2 717/4885LTB4R 135/4885LTB4R2 196/4885 |
| US-20110160243-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR5, S1PR3 | SRD5A2 717/4885LTB4R 135/4885LTB4R2 196/4885 |
| US-20130184307-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR5, S1PR3 | SRD5A2 717/4885LTB4R 135/4885LTB4R2 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.